ClinicalTrials.gg
Not yet recruitingNCT07093996Updated Jul 30, 2025

Endoscopic Pancreatic Duct Stent Placement Versus Conventional Approach in the Treatment of Early Phase Acute Pancreatitis

An interventional study of Endoscopic pancreatic duct stent placement and Conventional treatment of acute pancreatitis in early phase in Acute Pancreatitis (AP), sponsored by Almazov National Medical Research Centre. Not yet recruiting at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-30.

Sponsored by Almazov National Medical Research Centre · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The planned multicenter randomized study is aimed to assess the efficacy and safety of endoscopic pancreatic duct stenting in adult patients with acute pancreatitis. It is planned to include patients with early-stage nonbiliary pancreatitis in the study.

Read the detailed description

Endoscopic pancreatic duct stent placement is used to treat a variety of pancreatic diseases, including chronic pancreatitis, Wirsung duct strictures, pseudocysts in disconnected duct syndrome and as a preventive measure after endoscopic retrograde cholangiopancreatography. Despite the obvious progress, the greatest number of unsolved problems remain in the issues of using this manipulation in patients with acute pancreatitis. In particular, the perspectives of the pancreatic duct stent placement in treatment of acute pancreatitis early stages remain controversial.

On the one hand, the installation of a stent in the early acute pancreatitis stages helps to normalize the outflow of pancreatic juice from the pancreas and reduce intraductal pressure, leading to a beneficial effect, as evidenced by a number of researchers. On the other hand, stent placement may partially block the second-order pancreatic ducts or increase the risk of sterile pancreatitis contamination due to the development of reflux. In addition, one should not forget about a number of post-manipulation complications inherent in this procedure, including bleeding from the area of the major duodenal papilla, perforation of the duodenum, progression of pancreatic necrosis and cholangitis. Finally, the timing and indications for early endoscopic stenting of the pancreatic duct are not currently standardized, largely due to the fact that acute pancreatitis is a pathological condition that is difficult to predict.

Thus, although this manipulation seems perspective, due to the lack of evidence base, it is currently difficult to recommend it for use in wide clinical practice.

The planned multicenter randomized study is aimed to assess the efficacy and safety of endoscopic pancreatic duct stenting in adult patients with acute pancreatitis. It is planned to include patients with early-stage nonbiliary pancreatitis in the study.

02

Conditions studied

  • Acute Pancreatitis (AP)

Keywords

  • acute pancreatitis
  • endoscopic pancreatic duct stent placement
  • pancreatic necrosis
03

In context

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

This study's planned enrollment of 200 is above the median of 100 across 349 interventional studies indexed under Pancreatitis.

Browse Pancreatitis studies →

Lead sponsor

Almazov National Medical Research Centre is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of acute pancreatitis confirmed on the basis of at least 2 of the 3 diagnostic criteria according to the revised Atlanta classification
  2. Presence of organ failure signs (moderate and severe pancreatitis)
  3. of the patient

Exclusion criteria

Exclusion Criteria:

  1. Presence of other indications for endoscopic intervention on the major duodenal papilla (biliary pancreatitis with cholangitis, calculus of the major duodenal papilla, stenosis of the major duodenal papilla, etc.)
  2. Previous surgical interventions on the major duodenal papilla
  3. Diverticula of the major duodenal papilla
  4. Pregnancy
  5. Shock
  6. Coagulopathy (>1.5, blood \< 50*109/l
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Сomparison group

    Treatment measures will be performed in accordance with clinical guidelines and will include infusion therapy, pain relief, and nutritional support. Surgical interventions will also be performed based on estimated indications.

    Drug: Conventional treatment of acute pancreatitis in early phase

  • Experimental
    Study group

    Along with the generally accepted complex of therapeutic measures, endoscopic pancreatic duct stent placement will be performed

    Procedure: Endoscopic pancreatic duct stent placement

Interventions

  • ProcedureEndoscopic pancreatic duct stent placement

    Endoscopic pancreatic duct stent placement will be performed with a 5Fr Boston Scientific pancreatic stent (3-4 cm in length) within 24 hours from the randomization procedure. The stent will be removed on the 5th day after installation.

    Also known as: Wirsung stenting

  • DrugConventional treatment of acute pancreatitis in early phase

    Infusion therapy, pain relief, nutritional support and surgical procedure if needed

    Also known as: Conservative treatment

06

What researchers measure

Primary outcomes

  1. Mortality rate

    Data will be tabulated and statistically analyzed in terms of percentages

    Time frame: From enrollment to the end of treatment at 3 months

Secondary outcomes

  1. Incidence of complications associated with endoscopic pancreatic duct stent placement

    Frequency of duodenal bleeding, duodenal perforation, unsuccessful major duodenal papilla canulation etc. Data will be tabulated and statistically analyzed in terms of percentages

    Time frame: From endoscopic pancreatic duct stent placement to 3 months

  2. Rate of different pancreatic necrosis models

    Will be evaluated according CT-imaging: Model 1 - volume of pancreatic necrosis \< 30%, or not determined Model 2 - volume of pancreatic necrosis 30-50%, located in the distal pancreatic part Model 3 - volume of pancreatic necrosis 30-50% located in the proximal part Model 4 - volume of pancreatic necrosis 30-50% and more with separation of viable proximal and distal parts (disconnected duct syndrome) Data will be tabulated and statistically analyzed in terms of percentages

    Time frame: From enrollment to the 7th day of treatment

  3. Average Balthazar computed tomography severity index (0-10)

    A scoring system used to assess the severity of acute pancreatitis based on computed tomography scans. Data will be tabulated and statistically analyzed in terms of mean.

    Time frame: From enrollment to the 7th day of treatment

  4. Average SOFA (Sequential Organ Failure Assessment Score) score (0-24)

    Sequential Organ Failure Assessment Score. Data will be tabulated and statistically analyzed in terms of mean

    Time frame: From enrollment to the 7th day of treatment

  5. Incidence of other surgical interventions

    Frequency of other surgical interventions, such as abdominal drainage, retroperitoneal drainage, lumbotomy, laparotomy. Data will be tabulated and statistically analyzed in terms of percentages

    Time frame: From enrollment to the end of treatment at 3 months

  6. Number of participants with other surgical interventions

    Number of other surgical interventions, such as abdominal drainage, retroperitoneal drainage, lumbotomy, laparotomy

    Time frame: From enrollment to the end of treatment at 3 months

  7. Length of hospital stay

    Data will be tabulated and statistically analyzed in terms of length of hospital stay in days

    Time frame: From date of hospitalization until the date of discharge, assessed up to 3 months

  8. Number of participants with manifestation of diabetes mellitus

    Data will be tabulated and statistically analyzed in terms of percentages

    Time frame: From enrollment to the end of treatment at 3 months

07

Study locations

7 sites
  • Department of General Surgery, Sir Run Run Shaw Hospital
    Hangzhou, China
    • Yu Hong, PhD · Contactblueyu000@zju.edu.cn · 13605705907
    • Yu Hong, PhD · Principal investigator
    • Lou Songmei, PhD · Sub investigator
    • Guo Feng, PhD · Sub investigator
    • Song Shuping, PhD · Sub investigator
    • Litian Ye, PhD · Sub investigator
    • Shen Bo, PhD · Sub investigator
  • City Clinical Hospital No. 4
    Perm, Russia
    • Vladimir A Samarcev, PhD · Contactsamarcev-v@mail.ru · 89028017331
    • Vladimir A Samarcev, PhD · Principal investigator
    • Aleksei A Parshakov · Sub investigator
    • Natalia V Lozhkina · Sub investigator
  • Almazov National Medical Research Centre
    Saint Petersburg, 195220, Russia
    • Pavel A Kotkov, MD · ContactKotkovdr@mail.ru · 89062619231
    • Badri V Sigua, PhD · Principal investigator
    • Andrei B Singayevskiy, PhD · Sub investigator
    • Pavel A Kotkov, MD · Sub investigator
  • The City Hospital of the Holy Martyr Elizabeth
    Saint Petersburg, 195220, Russia
    • Pavel A Kotkov, MD · ContactKotkovdr@mail.ru · 89062619231
    • Sergei V Petrov, PhD · Principal investigator
    • Pavel A Kotkov, MD · Sub investigator
    • Andrei V Vovk, MD · Sub investigator
    • Denis A Chernyshov, MD · Sub investigator
    • Oleg Yu Orlov · Sub investigator
    • Rishat R Fevziev · Sub investigator
  • I.I. Dzhanelidze research institute of emergency medicine
    Saint Petersburg, Russia
    • Andrei E Demko, PhD · Contactopmu@emergency.spb.ru · 89215649140
    • Andrei E Demko, PhD · Principal investigator
    • Evgenii V Batig, MD · Sub investigator
    • Musa I Safoev, MD · Sub investigator
    • Ekaterina A Nikolaeva, MD · Sub investigator
  • Mariinskaya Hospital
    Saint Petersburg, Russia
    • Ivan A Solov'yev, PhD · Contactoog@mariin.ru · 89112411277
    • Ivan A Solov'yev, PhD · Principal investigator
    • Maria V Antipova, MD · Sub investigator
    • Maxim Yu Pletnev · Sub investigator
    • Shamsi Z Amari · Sub investigator
    • Aleksei A Gusev · Sub investigator
  • Volgograd State Medical University
    Volgograd, Russia
    • Igor V Mikhin, PhD · Contactpost@volgmed.ru · 89023621757
    • Igor V Mikhin, PhD · Principal investigator
    • Denis V Mikhaylov · Sub investigator
08

References and documents

Publications

  • Leppaniemi A, Tolonen M, Tarasconi A, Segovia-Lohse H, Gamberini E, Kirkpatrick AW, Ball CG, Parry N, Sartelli M, Wolbrink D, van Goor H, Baiocchi G, Ansaloni L, Biffl W, Coccolini F, Di Saverio S, Kluger Y, Moore E, Catena F. 2019 WSES guidelines for the management of severe acute pancreatitis. World J Emerg Surg. 2019 Jun 13;14:27. doi: 10.1186/s13017-019-0247-0. eCollection 2019. PubMed 31210778 ↗
  • ASGE Standards of Practice Committee; Anderson MA, Fisher L, Jain R, Evans JA, Appalaneni V, Ben-Menachem T, Cash BD, Decker GA, Early DS, Fanelli RD, Fisher DA, Fukami N, Hwang JH, Ikenberry SO, Jue TL, Khan KM, Krinsky ML, Malpas PM, Maple JT, Sharaf RN, Shergill AK, Dominitz JA. Complications of ERCP. Gastrointest Endosc. 2012 Mar;75(3):467-73. doi: 10.1016/j.gie.2011.07.010. No abstract available. PubMed 22341094 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Dec 2026, 15 months later.

Of 92 non-industry interventional studies with no phase under Pancreatitis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 15 months is below that.

Counting every sponsor, half of 95 studies reached it within 32 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2025
First posted
Jul 30, 2025
StartEst.
Sep 1, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Feb 1, 2027
Last update
Jul 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07093996
Lead sponsor
Almazov National Medical Research Centre
Responsible party
Kotkov Pavel (MD, associate professor of the General Surgery Department Almazov National Medical Research Centre, Almazov National Medical Research Centre) — Principal investigator
First posted
Jul 30, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Jul 30, 2025

Study contacts

Pavel A Kotkov, MD
Contact
Kotkovdr@mail.ru
89062619231
Badri V Sigua, PhD
Contact
dr.sigua@gmail.com
89111979343
Badri V Sigua, PhD
principal investigator · Almazov National Medical Research Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion